NOX-A12: Mobilizing CLL away from home

Blood

Volumn 123, Issue 7, 2014, Pages 952-953

  Marasca, Roberto ^a   Maffei, Rossana ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADM 3100; BENDAMUSTINE; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; NOX A 12; PLERIXAFOR; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; CELL MIGRATION; CHEMOSENSITIZATION; CHEMOTAXIS; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; HUMAN; LEUKEMIA CELL; LEUKOCYTE COUNT; LYMPHOCYTE HOMING; LYMPHOCYTE MIGRATION; MONOCYTE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NOTE; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CELL MOVEMENT; CHEMOKINE CXCL12; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 84897868174     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-542480     Document Type: Note

References (8)

1. Hoellenriegel J, Zboralski D, Maasch C, et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 2014;123(7):1032-1039.
2. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76(2):301-314. (Pubitemid 24046692)
3. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43(3):461-466. (Pubitemid 34232911)
4. Andritsos L, Byrd JC, Jones JA, et al. Preliminary results from a phase 1 dose escalation study to determine the maximum tolerated dose of Plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia [abstract]. Blood. 2010;116(21): 1017a. Abstract 2450.
5. Vater A, Klussmann S. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. Curr Opin Drug Discov Devel. 2003;6(2):253-261. (Pubitemid 36368380)
6. Amara A, Lorthioir O, Valenzuela A, et al. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem. 1999;274(34):23916-23925.
7. Vater A, Sahlmann J, Kröger N, et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin Pharmacol Ther. 2013;94(1):150-157.
8. Gobbi M, Steurer M, Caligaris-Cappio F, et al. Anti-CXCL12/SDF-1 Spiegelmer Nox-A12 alone and in combination with bendamustine and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL): results from a phase IIa study [abstract]. Blood. 2013;122(21). Abstract 1635.